Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

PRE-SURGERY BLOOD CELL RATIOS AND SURVIVAL IN PATIENTS WITH MALIGNANT GLIOMAS.

Experimental oncology·2026
Same author

MOLECULAR MARKERS IN PREDICTING THE OUTCOME OF DIFFUSE GLIOMA GRADE 4 TREATMENT.

Experimental oncology·2025
Same author

Evaluation of ocular and systemic endpoints after radiation of posterior uveal melanoma - A systematic review and meta-analysis.

Heliyon·2024
Same author

DENDRITIC CELLS IN GLIOBLASTOMA TREATMENT: A MODERN VIEW OF THE PROBLEM AND OWN EXPERIENCE.

Experimental oncology·2024
Same author

CLINICAL-AND-FUNCTIONAL ASSESSMENT OF THE EARLY POSTOPERATIVE OUTCOME OF SURGICAL TREATMENT OF PATIENTS WITH VESTIBULAR SCHWANNOMA.

Georgian medical news·2023
Same author

Sparing the hippocampus and the hypothalamic- pituitary region during whole brain radiotherapy: a volumetric modulated arc therapy planning study.

BMC cancer·2020

Related Experiment Video

Updated: Jun 10, 2025

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.3K

DIFFERENTIAL TREATMENT EFFECTS OF STANDARD AND HYPOFRACTIONATED RADIATION REGIMENS IN GLIOBLASTOMA PATIENTS.

O Glavatskyi1, A Gryazov1, V Stuley2

  • 1State Institution "Romodanov Neurosurgery Institute, National Academy of Medical Sciences of Ukraine", Kyiv, Ukraine.

Experimental Oncology
|October 13, 2024
PubMed
Summary
This summary is machine-generated.

Standard radiotherapy (SRT) improved survival over hypofractionated radiotherapy (HRT) only in specific glioblastoma subgroups with poor prognostic factors. Most patients showed no significant difference in cancer-specific survival between the two radiotherapy types.

More Related Videos

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

18.0K
Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform
07:57

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform

Published on: March 24, 2022

2.7K

Related Experiment Videos

Last Updated: Jun 10, 2025

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.3K
The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

18.0K
Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform
07:57

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform

Published on: March 24, 2022

2.7K

Area of Science:

  • Neuro-oncology
  • Radiation oncology
  • Biostatistics

Background:

  • Personalized treatment strategies require identifying subgroups with differential treatment effects (DTE).
  • Glioblastoma (GBM) survival analysis is crucial for optimizing patient outcomes.
  • Comparing standard radiotherapy (SRT) and hypofractionated radiotherapy (HRT) is essential for treatment selection.

Purpose of the Study:

  • To analyze DTE in glioblastoma (GBM) patients comparing standard radiotherapy (SRT) and hypofractionated radiotherapy (HRT).
  • To identify subgroups benefiting from specific radiotherapy regimens using multicluster modeling.
  • To retain statistical characteristics of the primary study cohort during subgroup analysis.

Main Methods:

  • Retrospective analysis of 159 newly diagnosed GBM patients.
  • Stratification into HRT (n=110) and SRT (n=49) groups.
  • Creation of 48 subgroups (multiclusters) based on 5 covariates: age, sex, resection radicality, chemotherapy, and Karnofsky status.
  • Comparison of cancer-specific survival (CSS) using interpolated Weibull curves and the Kolmogorov-Smirnov test.

Main Results:

  • SRT demonstrated superior CSS compared to HRT in only 3 of 48 modeled subgroups.
  • These 3 subgroups were characterized by non-radical tumor resection, no chemotherapy, and low Karnofsky status (≤70).
  • No significant CSS difference was observed between SRT and HRT in the remaining 45 subgroups (p ≥ 0.05).

Conclusions:

  • A novel multicluster modeling approach was developed for DTE analysis in GBM patients.
  • This method is suitable for analyzing DTE in smaller patient samples.
  • The approach can inform the design of future prospective trials for personalized GBM treatment strategies.